Newsroom

The announced price for alirocumab, the first PCSK9 inhibitor approved for use in the US, was the top story in managed care this week. Also, HHS announced $100 million available to combat substance abuse, and Medicare and Medicaid turn 50 years old.
Measure definitions to estimate the effects of cost sharing on adherence to medications prescribed together (ie, concurrent adherence) are lacking.
The study found that the geriatric population in the United States receives prescriptions for mental health drugs at more than twice the rate that younger adults do, but they present a lower rate of seeking psychiatric care.
A study published in JAMA Oncology presents a new tool that can predict disease recurrence in oropharyngeal cancer patients.
Proposed mergers of Aetna and Humana, and Anthem and Cigna, raise questions of whether consumers will continue to see competition in health insurance markets.
Earnings calls over the past 2 days for Express Scripts and Sanofi offered starkly different views of pricing for the first PCSK9 inhibitor to reach the US market.
Clinical pathways (CPs) are increasingly being utilized to improve quality of care and control healthcare costs in the United States. A new report from Avalere Health examines the development of CPs, use of evidence to inform their design, implementation processes, and their impact on quality of care, costs, and outcomes.
Middle-age men especially were more likely to have undiagnosed diabetes if they suffered from erectile dysfunction, according to the study.
Feature
$vacMongoViewPlus$